Epilepsy News

Enrolment concludes in Biohaven’s RISE3 trial for epilepsy - Biohaven has concluded enrolment in the pivotal RISE3 Phase II/III trial assessing the selective Kv7.2/7.3 channel activator, opakalim (BHV-7000), for refractory focal epilepsy. T ...

Seizure action plans: Management and educational tools in epilepsy care - Historically, seizure action plans have focused on certain high-risk groups—such as people with drug-resistant epilepsy and people with a history of status epilepticus or seizure clusters. Neurology ...

People with focal epilepsy often have seizures while driving before a diagnosis - Prior to being diagnosed with epilepsy, 5% of people with a type of epilepsy called focal epilepsy had a seizure while driving, according to a new study published in the June 7, 2023, online issue of ...

Living well with epilepsy: A diagnosis is not the end of the story - Over the past two weeks, we have explored what seizures and epilepsy are, corrected common myths, discussed seizure first aid, and examined the emotional, psychological, and cognitive challenges that ...

Seizure Burden in Resistant Epilepsy May Ease With the Tincture of Time - Nearly 70% of patients with focal treatment-resistant epilepsy (FTRE) experience fewer seizures over time, new results of a multicenter study showed. However, the improvements occurred independent of ...

What Is Neurofeedback Therapy And How Does It Work? - Ashwini Nadkarni, M.D., is a board-certified psychiatrist, Assistant Professor at Harvard Medical School and Interim Vice Chair for Faculty Affairs in the Department of Psychiatry at Brigham and Women ...

Rewiring Your Brain: Neurofeedback Goes Mainstream - See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. Will Strahl walked up to my door with a massive black briefcase in his ...

What Is Neurofeedback? - Whenever I mention that neurofeedback helped me regain my life after my multiple brain injuries — or that I’m now a neurofeedback provider — the first reaction is to ask me, what is neurofeedback? I’m ...

Elite athletes enhance their performance with 'neurofeedback'—and you can get a device for $99 - When you think of the training tools that professional athletes have at their disposal, high-tech sports equipment and state-of-the-art athletic facilities come to mind. But training for peak ...

Neurofeedback for ADHD: Significant, Lasting Improvement - Computer-based neurofeedback can produce significant and lasting improvement in attention and focus in children with attention-deficit/hyperactivity disorder (ADHD ...

CMIP as a novel candidate gene for neurodevelopmental and neuropsychiatric disorders - CMIP, a c-maf inducing protein that plays a key role in cytoskeletal remodeling, neuronal migration and synaptic formation, was first associated with specific language impairment and autism through the identification of a deletion in a single patient in 2012. Since then, only two additional individuals with CMIP deletions have been reported, both sharing features of autism and gastrointestinal ...

Clinical drug-oriented design, synthesis, and pharmacological evaluation of novel dual-target antiepileptic hybrid molecules - Epilepsy is a common neurological disorder frequently complicated by drug resistance, underscoring the urgent need for novel therapeutic agents. Using a pharmacophore hybridization strategy, we designed and synthesized two series of novel hybrid compounds by conjugating memantine (an NMDA receptor antagonist) with levetiracetam (a modulator of synaptic vesicle glycoprotein 2 A, SV2A) and lacosa...

UNC13A-related neurodevelopmental disorders in children: epilepsy phenotypes and antiseizure medication response - CONCLUSIONS: UNC13A variants represent an underrecognized cause of developmental and epileptic encephalopathy in children, characterized by refractory seizures, a high incidence of status epilepticus, and increased susceptibility to febrile seizures. Preliminary observations noted favorable clinical outcomes in a small subset of patients treated with LEV.

Switching from oxcarbazepine to eslicarbazepine in patients with focal epilepsy: A systematic review and single-arm meta-analysis - CONCLUSION: Switching from OXC to ESL may represent a pragmatic strategy for patients with OXC-related intolerance, particularly when treatment retention and tolerability are prioritized. However, the observational nature of the available evidence, together with substantial heterogeneity and wide confidence intervals, limits the precision and generalizability of pooled estimates.

Multifactorial Nature of Childhood Stroke Presents a Major Challenge for Diagnosis and Management: A Population-Based Study From Southern Finland - CONCLUSION: Childhood ischemic strokes in our population had heterogeneous causes and substantial long-term morbidity. Diagnostic delays were frequent, underscoring the need to improve recognition of paediatric stroke. The low recurrence rate highlights the importance of population-specific factors when interpreting risk and outcomes.

Characterizing Onset Limit and Surgical Outcome Factors in Type II Focal Cortical Dysplasia-Related Epilepsy - OBJECTIVES: To clarify the upper limit of epilepsy onset in focal cortical dysplasia (FCD) Type II (FCD)-related epilepsy and to investigate factors affecting long-term surgical outcomes from an open-source database.

Brain signal irregularity may provide clues to understanding epileptic process - Researchers propose a new method to differentiate signals from the epileptic focus from those recorded in other parts of the brain without the presence of an epileptic seizure. This technique may help detect epilepsy-induced features from these signals much quicker than conventional analysis techniques.

Breakthrough tech enables seizure localization in minutes - New research introduces a novel network analysis technology that uses minimally invasive resting state electrophysiological recordings to localize seizure onset brain regions and predict seizure outcomes in just 10 minutes.

Antidepressant use during pregnancy not linked to epilepsy in children - A new study suggests that antidepressant use by mothers during the first trimester of pregnancy does not increase the chances of epilepsy and seizures in babies.